First USFDA approval for Sun Pharma's Halol plant after warnings

This speciality drug, Sun claimed, is the first and only form of latanoprost that is not formulated with benzalkonium chloride

Sun Pharmaceutical Industries on Friday said it got approval for a glaucoma drug from the US Food and Drug Administration (USFDA) filed from its Halol plant in Gujarat, which had been under scanner for some time now.
 
Sun Pharma’s stocks reacted positively to the development and gained 2.35 per cent during day’s trade and ended at Rs 665.1 apiece on the BSE.
 
The abbreviated new drug application (ANDA) for this opthalmic drug was filed from the Halol plant, which was in trouble earlier this month after it received six adverse observations from the US drug regulator, two months